Evidence map›Paper›PMID 38302476›Full record

ArticleNature communications2024

Durvalumab and guadecitabine in advanced clear cell renal cell carcinoma: results from the phase Ib/II study BTCRC-GU16-043.

Yousef Zakharia, Eric A Singer, Satwik Acharyya, Rohan Garje, Monika Joshi, David Peace, Veera Baladandayuthapani, Annesha Majumdar, Xiong Li, Claudia Lalancette and 3 more

Registry-linked trialOpen access · goldAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03308396 (Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03308396 phase1 / phase2active not recruitingnot on this map

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer: Big Ten Cancer Research Consortium BTCRC-GU16-043

TypeinterventionalSponsorAjjai Alva, MDRan2017 to 2023Enrolled57ConditionsAdvanced Kidney Cancer, Kidney Cancer, Clear Cell Renal Cell CarcinomaArmsGuadecitabine, Durvalumab
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Getting the right combination to break the epigenetic code.Nature reviews. Clinical oncology · 2025
    Review
  5. Epigenetics-targeted drugs: current paradigms and future challenges.Signal transduction and targeted therapy · 2024
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Yousef ZakhariaUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA. yousef-zakharia@uiowa.edu.ORCID 0000-0001-9480-2626
Eric A SingerOhio State University Comprehensive Cancer Center, Columbus, OH, USA.
Satwik AcharyyaUniversity of Michigan, Ann Arbor, MI, USA.
Rohan GarjeUniversity of Iowa Holden Comprehensive Cancer Center, Iowa City, IA, USA.
Monika JoshiPenn State Cancer Institute, Hershey, PA, USA.
David PeaceUniversity of Illinois at Chicago, Chicago, IL, USA.ORCID 0000-0002-9403-760X
Veera BaladandayuthapaniUniversity of Michigan, Ann Arbor, MI, USA.
Annesha MajumdarBig Ten Cancer Research Consortium, Indianapolis, IN, USA.
Xiong LiUniversity of Michigan, Ann Arbor, MI, USA.
Claudia LalancetteBRCF Epigenomics Core University of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-6854-4034
Ilona KryczekUniversity of Michigan, Ann Arbor, MI, USA.ORCID 0000-0002-3130-2533
Weiping ZouUniversity of Michigan, Ann Arbor, MI, USA.ORCID 0000-0001-7952-3549
Ajjai AlvaUniversity of Michigan, Ann Arbor, MI, USA.
University of Michigan · USUniversity of Iowa · USPenn State Milton S. Hershey Medical Center · USRutgers, The State University of New Jersey · USUniversity of Illinois Chicago · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
CTL-killing capacity and cancer stiffness in cancer immunity and therapyR01CA261985 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WEIPING ZOU · 2022 to 2026
$3.2M
NCI NIH HHS P30 CA046592NCI NIH HHS R01 CA261985
6 · The paper itself

Abstract

Epigenetic modulation is well established in hematologic malignancies but to a lesser degree in solid tumors. Here we report the results of a phase Ib/II study of guadecitabine and durvalumab in advanced clear cell renal cell carcinoma (ccRCC; NCT03308396). Patients received guadecitabine (starting at 60 mg/m

Indexed as

Antibodies, MonoclonalCarcinoma, Renal CellAntineoplastic Combined Chemotherapy ProtocolsAzacitidineHumansAntibodies, MonoclonalAzacitidinedurvalumabguadecitabine

Identifiers

PMID38302476
PMCPMC10834488
OpenAlexW4391436651

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.